Experimental drug BIVV020 shows promise in rare blood disorder
NCT ID NCT04269551
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 26 times
Summary
This early-stage study tested a single dose of an experimental drug called BIVV020 in 12 adults with cold agglutinin disease, a rare condition where the immune system attacks red blood cells. The main goal was to check safety and how well the drug is tolerated. Researchers also looked at whether the drug reduces red blood cell breakdown and how it affects the immune system's complement pathway.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HAEMOLYTIC ANAEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :2760001
Essen, 45147, Germany
-
Investigational Site Number :3800001
Milan, Milano, 20122, Italy
-
Investigational Site Number :5280001
Amsterdam, 1105AZ, Netherlands
-
Investigational Site Number :5780001
Bergen, 5021, Norway
-
Investigational Site Number :8260001
London, London, City of, NW1 2PJ, United Kingdom
-
Investigational Site Number :8400002
Fayetteville, Georgia, 30214, United States
-
Investigational Site Number :8400004
Seattle, Washington, 98108, United States
-
Investigational Site Number :8400006
The Bronx, New York, 10467, United States
-
Investigational Site Number :8400008
Pittsburgh, Pennsylvania, 15232, United States
-
Investigational Site Number :8400009
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.